Understanding the role of PARP1 in blood disorders and targeted treatments
Implications of PARP1 in myelodysplastic syndromes and targeted therapy
This study is looking at how certain gene changes in myelodysplastic syndromes (MDS) affect blood cell production and how a protein called PARP1 helps fix DNA damage, with the goal of finding new treatments that might help patients with MDS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11080877 on NIH RePORTER |
What this research studies
This research investigates myelodysplastic syndromes (MDS), which are disorders caused by ineffective blood cell production due to mutations in specific genes. The study focuses on how these mutations lead to genomic instability and the role of PARP1 in managing DNA damage associated with these mutations. By exploring the relationship between R-loops and PARP1, the research aims to identify new treatment strategies that could target these vulnerabilities in patients with MDS. Patients may be involved in trials assessing the effectiveness of PARP inhibitors as a potential therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with myelodysplastic syndromes, particularly those with mutations in RNA splicing factor genes.
Not a fit: Patients without myelodysplastic syndromes or those with other unrelated blood disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with myelodysplastic syndromes, improving their treatment outcomes.
How similar studies have performed: Previous research has shown promising results in targeting similar genetic vulnerabilities in blood disorders, suggesting that this approach may be effective.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Nguyen, Dang Hai — University of Minnesota
- Study coordinator: Nguyen, Dang Hai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.